ArticleiScience2026
Cholesterol metabolism dysregulated by key HBV mutations revealed through multi-omics profiling.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic hepatitis B virus (HBV) infection shows variable progression linked to specific viral mutations. This multi-omics study analyzed 108 patients with chronic HBV, stratified into wild-type, G1896A, A1762T/G1764A, and A1762T/G1764A + G1896A variant groups. Serum proteomics and metabolomics revealed that patients infected with HBV A1762T/G1764A or the double mutants had significantly higher ALT and AST levels, correlating with disease severity. Compared to wild-type, proteomic analysis identified 59, 54, and 79 differentially expressed proteins in the G1896A, double mutant, and combined mutant groups, respectively. Metabolomics showed 201, 242, and 226 altered metabolites in the same groups. Integrated pathway analysis consistently pinpointed cholesterol metabolism as the most disrupted pathway. From this pathway, six key proteins and metabolites emerged as potential combined biomarkers for distinguishing between these HBV variants, linking viral genotype to host molecular response and clinical outcome.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.